LON:MPH Mereo BioPharma Group plc (MPH.L) (MPH) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Mereo BioPharma Group plc (MPH.L) Stock (LON:MPH) 30 days 90 days 365 days Advanced Chart Remove Ads Get MPH alerts:Sign Up Key Stats Today's Range N/A50-Day Range 26.50▼ 26.5052-Week Range N/AVolume49,264 shsAverage Volume333,975 shsMarket Capitalization£89.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.Read More… Remove Ads Receive MPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter. Email Address MPH Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), Tenax Therapeutics (TENX) and Nkarta (NKTX)March 31 at 5:35 PM | markets.businessinsider.comMereo BioPharma reports FY24 EPS (6c), consensus (5c)March 27, 2025 | markets.businessinsider.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.April 1, 2025 | Porter & Company (Ad)Buy Recommendation for Mereo Biopharma Group Plc Driven by Promising Clinical Programs and Strategic PositioningJanuary 16, 2025 | markets.businessinsider.comMereo BioPharma initiated with an Outperform at LifeSci CapitalDecember 23, 2024 | markets.businessinsider.comMereo Biopharma’s Potential in Rare Disease Therapy: Buy Rating and Strategic Partnership with UltragenyxDecember 23, 2024 | markets.businessinsider.comMereo BioPharma files for common stock offering by holdersNovember 26, 2024 | msn.comMereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comSee More Headlines MPH Stock Analysis - Frequently Asked Questions How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter? Mereo BioPharma Group plc (MPH.L) (LON:MPH) announced its earnings results on Tuesday, September, 29th. The company reported ($105.00) earnings per share (EPS) for the quarter. How do I buy shares of Mereo BioPharma Group plc (MPH.L)? Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group plc (MPH.L) investors own include Bausch Health Companies (BHC), Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Bristol-Myers Squibb (BMY), Galaxy Digital (BRPHF) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings9/29/2020Today4/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:MPH CIKN/A Webmereobiopharma.com Phone44 33 3023 7300FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio164.26 Current Ratio2.98 Quick Ratio2.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow1.55 Book ValueGBX 7.20 per share Price / BookN/AMiscellaneous Outstanding Shares338,713,984Free FloatN/AMarket Cap£89.76 million OptionableNot Optionable BetaN/A 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (LON:MPH) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc (MPH.L) Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group plc (MPH.L) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.